BACKGROUND AIMS: A phase I trial examined the ability of immunotherapy to mobilize progenitor and activated T cells. METHODS: Interleukin (IL)-2 was administered subcutaneously for 11 days, with granulocyte (G)-colony-stimulating factor (CSF) (5 mcg/kg/day) and granulocyte-macrophage (GM)-CSF (7.5 mcg/kg/day) added for the last 5 days. Leukapheresis was initiated on day 11. Thirteen patients were treated (myeloma n = 11, non-Hodgkin's lymphoma n = 2). RESULTS: Toxicities were minimal. IL-2 was stopped in two patients because of capillary leak (n = 1) and diarrhea (n = 1). Each patient required 2.5 leukaphereses (median; range 1-3) to collect 3.2 x 10⁶ CD34+ cells/kg (median; range 1.9-6.6 x 10⁶/kg). Immune mobilization increased the number of CD3+ CD8+ T cells (P = 0.002), CD56+ natural killer (NK) cells (P = 0.0001), CD8+ CD56+ T cells (P = 0.002) and CD4+ CD25+ cells (P = 0.0001) compared with cancer patients mobilized with G-CSF alone. There was increased lysis of myeloma cells after 7 days (P = 0.03) or 11 days (P = 0.02). The maximum tolerated dose of IL-2 was 1 x 10⁶ IU/m²/day. CONCLUSIONS: Immune mobilization is well tolerated with normal subsequent marrow engraftment. As cells within the graft influence lymphocyte recovery, an increased number of functional lymphocytes may result in more rapid immune reconstitution.
BACKGROUND AIMS: A phase I trial examined the ability of immunotherapy to mobilize progenitor and activated T cells. METHODS:Interleukin (IL)-2 was administered subcutaneously for 11 days, with granulocyte (G)-colony-stimulating factor (CSF) (5 mcg/kg/day) and granulocyte-macrophage (GM)-CSF (7.5 mcg/kg/day) added for the last 5 days. Leukapheresis was initiated on day 11. Thirteen patients were treated (myeloma n = 11, non-Hodgkin's lymphoma n = 2). RESULTS:Toxicities were minimal. IL-2 was stopped in two patients because of capillary leak (n = 1) and diarrhea (n = 1). Each patient required 2.5 leukaphereses (median; range 1-3) to collect 3.2 x 10⁶ CD34+ cells/kg (median; range 1.9-6.6 x 10⁶/kg). Immune mobilization increased the number of CD3+ CD8+ T cells (P = 0.002), CD56+ natural killer (NK) cells (P = 0.0001), CD8+ CD56+ T cells (P = 0.002) and CD4+ CD25+ cells (P = 0.0001) compared with cancerpatients mobilized with G-CSF alone. There was increased lysis of myeloma cells after 7 days (P = 0.03) or 11 days (P = 0.02). The maximum tolerated dose of IL-2 was 1 x 10⁶ IU/m²/day. CONCLUSIONS: Immune mobilization is well tolerated with normal subsequent marrow engraftment. As cells within the graft influence lymphocyte recovery, an increased number of functional lymphocytes may result in more rapid immune reconstitution.
Authors: L F Porrata; M R Litzow; D J Inwards; D A Gastineau; S B Moore; A A Pineda; K L Bundy; D J Padley; D Persky; S M Ansell; I N M Micallef; S N Markovic Journal: Bone Marrow Transplant Date: 2004-02 Impact factor: 5.483
Authors: L F Porrata; M A Gertz; S M Geyer; M R Litzow; D A Gastineau; S B Moore; A A Pineda; K L Bundy; D J Padley; D Persky; M Q Lacy; A Dispenzieri; D S Snow; S N Markovic Journal: Leukemia Date: 2004-06 Impact factor: 11.528
Authors: K H Grabstein; D L Urdal; R J Tushinski; D Y Mochizuki; V L Price; M A Cantrell; S Gillis; P J Conlon Journal: Science Date: 1986-04-25 Impact factor: 47.728
Authors: T Demirer; C D Buckner; B Storer; K Lilleby; S Rowley; R Clift; F R Appelbaum; R Storb; W I Bensinger Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: C Cesana; C Carlo-Stella; E Regazzi; D Garau; G Sammarelli; C Caramatti; A Tabilio; L Mangoni; V Rizzoli Journal: Bone Marrow Transplant Date: 1998-03 Impact factor: 5.483
Authors: J E Talmadge; E C Reed; A Kessinger; C A Kuszynski; G A Perry; C L Gordy; K C Mills; M L Thomas; S J Pirruccello; B A Letheby; M A Arneson; J D Jackson Journal: Bone Marrow Transplant Date: 1996-01 Impact factor: 5.483
Authors: S S Joshi; J C Lynch; S Z Pavletic; S R Tarantolo; S J Pirruccello; A Kessinger; M R Bishop Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: I J Webb; C E Eickhoff; A D Elias; L J Ayash; C A Wheeler; G N Schwartz; G D Demetri; K C Anderson Journal: Transfusion Date: 1996-02 Impact factor: 3.157
Authors: Kenneth R Meehan; Laleh Talebian; Tor D Tosteson; John M Hill; Zbigniew Szczepiorkowski; Charles L Sentman; Marc S Ernstoff Journal: Biol Blood Marrow Transplant Date: 2012-09-10 Impact factor: 5.742
Authors: Laleh Talebian; Jia Yan Wu; Dawn A Fischer; John M Hill; Zbigniew M Szczepiorkowski; Marc S Ernstoff; Charles L Sentman; Kenneth R Meehan Journal: Front Biosci (Elite Ed) Date: 2011-06-01
Authors: Gwang Hun Jeong; Keum Hwa Lee; I Re Lee; Ji Hyun Oh; Dong Wook Kim; Jae Won Shin; Andreas Kronbichler; Michael Eisenhut; Hans J van der Vliet; Omar Abdel-Rahman; Brendon Stubbs; Marco Solmi; Nicola Veronese; Elena Dragioti; Ai Koyanagi; Joaquim Radua; Jae Il Shin Journal: J Clin Med Date: 2019-01-26 Impact factor: 4.241